30-Jun-2006
Completion of Acquisition or Disposition of Assets, Financ
ITEM 2.01. COMPLETION OR ACQUISITION OF ASSETS.
As previously reported under Item 2.01 of the Current Report on Form 8-K filed by American Oriental Bioengineering, Inc., a Nevada corporation (the "Registrant" or "AOB") with the Securities and Exchange Commission on April 24, 2006 (the "April 8-K"), Yield Chance Investments Limited, a wholly-owned subsidiary formed under the laws of the British Virgin Islands (the "Subsidiary") completed the acquisition of Guangxi Lingfeng Pharmaceutical Company Limited, a Chinese corporation ("Lingfeng"), pursuant to an Acquisition Agreement (the "Agreement") by and among AOB, Lingfeng and Xiaosheng Yu, the sole stockholder of Lingfeng. Under the terms of the Agreement, the Subsidiary acquired all of the outstanding capital stock of Lingfeng. The description of the acquisition included in the April 8-K is incorporated by reference herein.
This Current Report on Form 8-K/A provides the historical financial statements of the business acquired under Item 9.01(a) and the pro forma financial information under Item 9.01(b), which financial statements and information were not included in the April Form 8-K.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED. Guangxi Lingfeng Pharmaceutical Company Limited audited Financial Statements as of and for the years ended December 31, 2004 and 2005 and unaudited condensed financial statements as of March 31, 2006 and for the three months ended March 31, 2006 and 2005 are filed as Exhibit 99.1 to this amendment and incorporated herein by reference.
(b) PRO FORMA FINANCIAL INFORMATION. The pro forma financial information with respect to the transaction described in Item 2.01 is filed as Exhibit 99.2 to this amendment and incorporated herein by reference.
|
